These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33333686)

  • 1. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
    Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
    Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.
    Zhang J; Zhou N; Deng H; Chen X; Chen Q; Wang Q; Sun L; Wen Y; Cao X; Luo Z; Zhang J; Zhu W; Guo L
    Lung Cancer; 2023 Apr; 178():11-19. PubMed ID: 36758321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic features of Chinese small cell lung cancer.
    Liu J; Zhao Z; Wei S; Li B; Zhao Z
    BMC Med Genomics; 2022 May; 15(1):117. PubMed ID: 35596192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
    Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
    J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
    Si H; Kuziora M; Quinn KJ; Helman E; Ye J; Liu F; Scheuring U; Peters S; Rizvi NA; Brohawn PZ; Ranade K; Higgs BW; Banks KC; Chand VK; Raja R
    Clin Cancer Res; 2021 Mar; 27(6):1631-1640. PubMed ID: 33355200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
    Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH
    BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer.
    Feng Y; Liu Y; Yuan M; Dong G; Zhang H; Zhang T; Chang L; Xia X; Li L; Zhu H; Xing P; Wang H; Shi Y; Wang Z; Hu X
    Cancer Res Treat; 2022 Jul; 54(3):753-766. PubMed ID: 34645133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer.
    Zhou M; Fan J; Li Z; Li P; Sun Y; Yang Y; Zhou X; Wang J; Wang Y; Qi H; Cai W; Dai X; Hirsch FR
    Respir Res; 2019 Nov; 20(1):248. PubMed ID: 31699089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical correlation of extensive-stage small-cell lung cancer genomics.
    Dowlati A; Lipka MB; McColl K; Dabir S; Behtaj M; Kresak A; Miron A; Yang M; Sharma N; Fu P; Wildey G
    Ann Oncol; 2016 Apr; 27(4):642-7. PubMed ID: 26802149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable Alterations.
    Yang J; Wang X; Lu J; Chen H; Zhao X; Gao C; Bai Y; Zhang Q; Fu X; Zhang X
    J Cancer; 2021; 12(17):5099-5105. PubMed ID: 34335926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
    Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM
    J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.
    Devarakonda S; Sankararaman S; Herzog BH; Gold KA; Waqar SN; Ward JP; Raymond VM; Lanman RB; Chaudhuri AA; Owonikoko TK; Li BT; Poirier JT; Rudin CM; Govindan R; Morgensztern D
    Clin Cancer Res; 2019 Oct; 25(20):6119-6126. PubMed ID: 31300452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab.
    Herbreteau G; Langlais A; Greillier L; Audigier-Valette C; Uwer L; Hureaux J; Moro-Sibilot D; Guisier F; Carmier D; Madelaine J; Otto J; Souquet PJ; Gounant V; Merle P; Molinier O; Renault A; Rabeau A; Morin F; Denis MG; Pujol JL
    J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33261056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy.
    Li L; Wang Y; Shi W; Zhu M; Liu Z; Luo N; Zeng Y; He Y
    Cancer Med; 2019 Dec; 8(18):7669-7678. PubMed ID: 31692284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
    Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
    Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
    Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
    J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
    Hu J; Wang Y; Zhang Y; Yu Y; Chen H; Liu K; Yao M; Wang K; Gu W; Shou T
    Cancer Med; 2019 Aug; 8(9):4338-4347. PubMed ID: 31199602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
    Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J
    Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease.
    Iams WT; Kopparapu PR; Yan Y; Muterspaugh A; Zhao Z; Chen H; Cann C; York S; Horn L; Ancell K; Wyman K; Bertucci C; Shaffer T; Hodsdon LA; Garg K; Hosseini SA; Lim LP; Lovly CM
    JTO Clin Res Rep; 2020 Jun; 1(2):100024. PubMed ID: 34589931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.